In adult patients with MMN, GAMMAGARD LIQUID provided improvement in grip strength and reduced disability as compared to placebo

In the largest clinical trial in 44 patients with MMN to date,3
GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% was shown to1:

  • Treatment with GAMMAGARD LIQUID in adults with MMN improved functioning by effectively maintaining and improving grip strength and reducing disability compared to placebo1

Formulated with your needs in mind

  • sucrose1
  • added sugars1
  • added sodium1
  • added preservatives1

The packaging is not made with natural rubber latex.1

Stabilized and buffered with glycine.1

References:

  1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.
  2. The Marketing Research Bureau. The Plasma Proteins Market in the United States 2015. Orange, CT: Marketing Research Bureau, Inc; 2016.
  3. Data on file. Baxter Healthcare Corporation. 2011.

QUESTIONS ABOUT IMMUNOGLOBULIN (IgG)?

Call MyIgSource at 1-855-250-5111.

1-855-250-5111

SUPPORT IS HERE FOR YOU

With MyIgSource, you are not alone.

Explore:

  • Educational Resources and Tools
  • Patient and Nurse Advocates
  • Medication Access Support for Eligible Patients

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Expand

Please expand for Indication and Detailed Important Safety Information.

Important Safety Information

What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.